納思達(002180.SZ):控股子公司擬22億元投建芯片研發相關項目
格隆匯10月28日丨納思達(002180.SZ)公佈,2021年10月28日,公司召開第六屆董事會第二十四次會議,審議通過了《關於控股子公司與中國(上海)自由貿易試驗區臨港新片區管理委員會擬簽署投資協議書的議案》。公司控股子公司珠海艾派克微電子有限公司(以下簡稱"艾派克微電子"或"艾派克")擬總投資22億元在國際創新協同區內建設芯片研發相關項目。
公吿稱,此次交易旨在推動艾派克微電子芯片項目研發、完善產業鏈,聯動上下游優質資源,充分發揮產業協同效應,推進落實其戰略規劃和產業佈局,有利於公司未來的長遠發展,符合公司和全體股東的利益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.